The global RNAi Therapeutics Market was valued at USD 1.4 Billion in 2021 and it is anticipated to grow up to USD 3.8 Billion by 2031, at a CAGR of 10.4% during the forecast period.
New York, Global RNAi Therapeutics Market from Global Insight Services is the only authoritative source for intelligence on the RNAi Therapeutics Market . The report will provide you with an analysis of the impact of the latest market disruptions such as the Russo-Ukrainian War and Covid-19 on the market. The report provides a qualitative analysis of the market using various frameworks such as Porters Analysis and PESTLE. The report includes in-depth segmentation and market size data by categories, product types, applications, and geographic regions. The report also includes a comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as mergers and acquisitions activities in the market.
Download sample report: https://www.globalinsightservices.com/request-sample/GIS10510
A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.
Major Players in the Global RNAi Therapeutics Market
The key players in the RNAi Therapeutics Market Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.), among others.
Free customization available – https://www.globalinsightservices.com/request-customization/GIS10510
Market Trends and Drivers
Rising cases of chronic diseases
The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period of 2023 to 2030.
Increasing collaborative activities
The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals’ rapidly growing pipeline of investigational RNAi therapeutics based on the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform.” In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.
Purchase This Market Research Report – https://www.globalinsightservices.com/checkout/single_user/GIS10510
Global RNAi Therapeutics Market Segmentation
By Type
- Small Interfering RNAS
- Microrna
By Application
- Oncology
- Cardiovascular Diseases (CVDs)
- Respiratory Disorders
- Neurodegenerative Disorder
- Genetic Disorders
- Others
By Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intra-dermal Injections
- Intraperitoneal Injections
- Topical Delivery
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
With Global Insight Services, you receive:
- 10-year forecasts to help you make strategic decisions
- In-depth segmentation that can be customized according to your requirements
- Free consultation with the lead analyst of the report
- Excel data package included with all report purchases
- Robust and transparent research methodology
Leading research and solutions centered around the market player for the next decade according to the current market scenario
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1–833–761–1700